Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review
To determine the efficacy and safety of heparin (unfractionated heparin (UFH) or low-molecular-weight-heparin (LMWH)) and fondaparinux in improving the survival of patients with cancer.
Methods: We conducted in January 2007 a comprehensive search for relevant randomized clinical trials (RCTs). We used a standardized form to extract in duplicate data on methodological quality, participants, interventions and outcomes of interest including all cause mortality, thromboembolic events, and bleeding events.
We assessed the methodological quality for each outcome by grading the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology
Results: Of 3986 identified citations, we included 5 RCTs, none of which evaluated fondaparinux. The quality of evidence was high for survival, low for major and minor bleeding, and very low for DVT.
Heparin therapy was associated with a statistically and clinically significant survival benefit (hazard ratio (HR)=0.77; 95%CI=0.65-0.91). In subgroup analyses, patients with limited small cell lung cancer experienced a clear survival benefit (HR=0.56; 95%CI=0.38-0.83).
The survival benefit was not statistically significant for either patients with extensive small cell lung cancer (HR=0.80; 95%CI=0.60-1.06) or patients with advanced cancer (HR=0.84; 95%CI=0.68-1.03). The increased risk of bleeding with heparin was not statistically significant (relative risk (RR)=1.78; 95%CI=0.73-4.38).
Conclusion: This review suggests a survival benefit of heparin in cancer patients in general, and in patients with limited small cell lung cancer in particular.
Author: Elie A Akl, Frederiek F van Doormaal, Maddalena Barba, Ganesh Kamath, Seo Young Kim, Saskia Kuipers, Saskia Middeldorp, Victor Yosuico, Heather O Dickinson and Holger J Schunemann
Credits/Source: Journal of Experimental &Clinical Cancer Researc
Published on: 2008-05-15
Limited copyright is granted for you to use and/or republish any story on this site for
any legitimate media purpose as long as you reference 7thSpace and any source mentioned in the story above. Please
make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.
Social Bookmarking
Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo
|
|
